GlassScriptPhysician profile
Adam C Stage
NPI 1780651489
$8,113.08
in general payments reported to CMS, 2019-2025
39 companies · $401 in 2025
The $401 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $320 · 2021: $245 · 2022: $979 · 2023: $2,771 · 2024: $2,336 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,981 · Travel and Lodging: $2,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.86 |
| Travel and Lodging | $2,526.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $3,022.90 | 2021-2024 | Axonics, Bulkamid |
| Bluewind Medical | $747.92 | 2024 | Revi |
| Medtronic USA, INC. | $572.90 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $435.92 | 2019-2024 | Aveed, Xiaflex, Edex |
| Abbvie INC. | $354.27 | 2019-2024 | Botox, Lupron Depot |
| Astellas Pharma US INC | $297.49 | 2019-2024 | Myrbetriq |
| Janssen Biotech, INC. | $281.94 | 2019-2022 | |
| Amgen INC. | $258.51 | 2020-2024 | Prolia |
| Sumitomo Pharma America, INC. | $195.57 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $184.86 | 2020-2025 | Spaceoar Vue System - 10ml, Axonics |
| Procept Biorobotics Corporation | $178.58 | 2020-2025 | Aquabeam System |
| Coloplast Corp | $163.58 | 2022-2023 | Speedicath |
| Progenics Pharmaceuticals, INC. | $159.72 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.31 | 2022-2024 | |
| Medtronic, INC. | $125.19 | 2022-2023 | Interstim, Nuro |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $122.05 | 2024-2025 | Xiaflex, Aveed |
| Myriad Genetic Laboratories, INC. | $93.79 | 2023-2025 | Prolaris, Myrisk |
| Dendreon Pharmaceuticals LLC | $93.40 | 2019-2024 | Provenge |
| Pfizer INC. | $75.24 | 2019-2020 | |
| Antares Pharma, INC. | $73.12 | 2020-2024 | Xyosted |
| Edap Technomed INC | $52.15 | 2022 | |
| Allergan, INC. | $49.87 | 2019 | |
| Valencia Technologies Corporation | $47.52 | 2024 | Ecoin Device Kit |
| Sun Pharmaceutical Industries INC. | $44.39 | 2022-2023 | Yonsa |
| Myovant Sciences INC. | $43.16 | 2021-2022 | |
| Teleflex LLC | $42.22 | 2022 | |
| Ferring Pharmaceuticals INC. | $40.76 | 2019-2025 | Adstiladrin |
| Astrazeneca Pharmaceuticals LP | $37.22 | 2023-2024 | Lynparza |
| Urovant Sciences INC | $24.87 | 2021 | |
| Calyxo, INC. | $24.09 | 2025 | Cvac Aspiration System |
| Laborie Medical Technologies Corp. | $20.78 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $20.54 | 2022 | |
| Blue Earth Diagnostics | $19.97 | 2019 | |
| Tolmar, INC. | $19.29 | 2024 | |
| Smith+Nephew, INC. | $19.08 | 2023 | Grafix |
| Merck Sharp & Dohme LLC | $17.15 | 2022 | |
| Civco Medical Instruments | $9.76 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$367,880.82 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Stage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.